Abstract
Factor I (FI) is a soluble, 88 kDa glycoprotein present in plasma at a concentration of approximately 35 mg/L. FI inhibits all complement pathways as it degrades activated C4b and C3b when these are bound to a cofactor such as C4b-binding protein or factor H. Here, we describe a method for purification of FI from human plasma, which is based on affinity chromatography followed by anion exchange chromatography. We also describe a functional assay, in which activity of FI can be assessed.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Morris KM, Aden DP, Knowles BB et al (1982) Complement biosynthesis by the human hepatoma-derived cell line HepG2. J Clin Invest 70:906–913
Goldberger G, Arnaout MA, Aden D et al (1984) Biosynthesis and postsynthetic processing of human C3b/C4b inactivator (factor I) in three hepatoma cell lines. J Biol Chem 259:6492–6497
Nilsson SC, Karpman D, Vaziri-Sani F et al (2007) A mutation in factor I that is associated with atypical hemolytic uremic syndrome does not affect the function of factor I in complement regulation. Mol Immunol 44:1835–1844
Ullman CG, Chamberlain D, Ansari A et al (1998) Human complement factor I: its expression by insect cells and its biochemical and structural characterisation. Mol Immunol 35:503–512
Chamberlain D, Ullman CG, Perkins SJ (1998) Possible arrangement of the five domains in human complement factor I as determined by a combination of X-ray and neutron scattering and homology modeling. Biochemistry 37:13918–13929
Tsiftsoglou SA, Willis AC, Li P et al (2005) The catalytically active serine protease domain of human complement factor I. Biochemistry 44:6239–6249
Roversi P, Johnson S, Caesar JJ et al (2011) Structural basis for complement factor I control and its disease-associated sequence polymorphisms. Proc Natl Acad Sci USA 108:12839–12844
Tsiftsoglou SA, Sim RB (2004) Human complement factor I does not require cofactors for cleavage of synthetic substrates. J Immunol 173:367–375
Amadei N, Baracho GV, Nudelman V et al (2001) Inherited complete factor I deficiency associated with systemic lupus erythematosus, higher susceptibility to infection and low levels of factor H. Scand J Immunol 53:615–621
Nilsson SC, Trouw LA, Renault N et al (2009) Genetic, molecular and functional analyses of complement factor I deficiency. Eur J Immunol 39:310–323
Sadallah S, Gudat F, Laissue JA et al (1999) Glomerulonephritis in a patient with complement factor I deficiency. Am J Kidney Dis 33:1153–1157
Bienaime F, Dragon-Durey MA, Regnier CH et al (2010) Mutations in components of complement influence the outcome of Factor I-associated atypical hemolytic uremic syndrome. Kidney Int 77:339–349
Esparza-Gordillo J, Jorge EG, Garrido CA et al (2006) Insights into hemolytic uremic syndrome: segregation of three independent predisposition factors in a large, multiple affected pedigree. Mol Immunol 43:1769–1775
Kavanagh D, Kemp EJ, Mayland E et al (2005) Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome. J Am Soc Nephrol 16:2150–2155
Nilsson SC, Kalchishkova N, Trouw LA et al (2010) Mutations in complement factor I as found in atypical hemolytic uremic syndrome lead to either altered secretion or altered function of factor I. Eur J Immunol 40:172–185
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media, New York
About this protocol
Cite this protocol
Nilsson, S.C., Blom, A.M. (2014). Purification and Functional Characterization of Factor I. In: Gadjeva, M. (eds) The Complement System. Methods in Molecular Biology, vol 1100. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-724-2_15
Download citation
DOI: https://doi.org/10.1007/978-1-62703-724-2_15
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-62703-723-5
Online ISBN: 978-1-62703-724-2
eBook Packages: Springer Protocols